Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension

Özyıldız, Ali Gökhan; Eroğlu, Serpil; Bal, Uğur Abbas; Atar, İlyas; Okyay, Kaan; Müderrisoğlu, Haldun

doi:10.1177/1074248416644987

Cited by 21 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three previous studies have also reported a neutral effect of nebivolol on HDL cholesterol levels, [26][27][28] and two studies even reported a reduction in HDL cholesterol levels. 29,30 In the present study, nebivolol treatment lowered HDL cholesterol levels and seemed to attenuate the effect of rosuvastatin on increasing HDL cholesterol levels. Reasons for the different results among studies could not be clarified as the treatment schedule and inclusion criteria were quite different.…”

supporting

confidence: 49%

<p>Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia</p>

Rhee

Kim

Ahn

et al. 2020

DDDT

View full text Add to dashboard Cite

supporting

confidence: 49%

<p>Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia</p>

Rhee

Kim

Ahn

et al. 2020

DDDT

View full text Add to dashboard Cite

“…A few studies elucidated the more favourable side effect profile of nebivolol. Ozyildiz et al compared carvedilol and nebivolol in different metabolic parameters and found both drugs to have favourable effects on blood glucose, insulin sensitivity and total cholesterol levels.…”

Section: Discussionmentioning

confidence: 99%

Nebivolol in the treatment of arterial hypertension

Olawi

Krüger

Grimm

et al. 2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

This MiniReview reports the current knowledge about the treatment of arterial hypertension with the third‐generation beta‐adrenoceptor antagonist (BAA) nebivolol. Furthermore, it reviews the advantages of nebivolol compared to the earlier generation of BAAs with respect to their different pharmacological properties. Beta‐adrenoceptor antagonists are a class of drugs applied for several different conditions, including hypertension and heart failure. They differ significantly in their pharmacological properties, including varying β1/β2‐selectivity and/or exertion of additive effects on the heart and circulation. Although these drugs have been a part of hypertensive therapy for about 40 years, the outcome of large clinical trials has put the role of BAAs into question. However, most of these results were based on first‐ and second‐generation BAAs and cannot be translated directly into third‐generation drugs. The third‐generation BAA nebivolol has the highest β1‐selectivity seen so far, together with additional vasodilating and anti‐oxidative properties. It is currently applied in the treatment of hypertension and congestive heart failure. Nebivolol has a unique pharmacological profile, despite showing similar blood pressure‐lowering effects, and has certain advantages in the treatment of hypertension compared to the previous generations of BAAs. This includes significant improvements in endothelial dysfunction, central haemodynamics and the degree of erectile dysfunction in men, a neutral/beneficial metabolic profile and lastly a more favourable side effect profile. It is widely beneficial for, for example, sexually active men and patients with comorbidities such as type II diabetes mellitus, metabolic syndrome and chronic obstructive lung disorders. Whether the advantages translate to an improved long‐term clinical outcome remains to be clarified, and ongoing prospective studies will show this in the future.

show abstract

“…Patients with DM treated with long-term beta-blocker have recently been evaluated by a prospective observational study, as well as a post hoc analysis from the ACCORD study, suggesting increased all-cause death in DM patients treated with beta-blockers 40,41 . Carvedilol and nebivolol may be preferred because of their ability to improve insulin sensitivity, with no negative effects on glycemic control 42,43 .…”

Section: Specific Cardiovascular Therapiesmentioning

confidence: 99%

Chronic heart failure and diabetes mellitus: two unsuitably matched partners

MUNTEANU¹,

Gheorghe²,

Stănescu³

et al. 2020

Arch Balk Med Union

View full text Add to dashboard Cite

Insuffisance cardiaque chronique et diabète sucré: deux partenaires mal assortis Le diabète sucré (DS) et l'insuffisance cardiaque (IC) sont souvent associés et chaque maladie augmente indépendamment le risque pour l'autre. Il est bien reconnu que le diabète est un facteur de risque de mortalité chez les personnes souffrant d'insuffisance cardiaque. Le risque d'incidence de l'IC chez les patients atteints de DS augmente avec l'âge, l'obésité, la rétinopathie, l'hypertension, la maladie coronarienne, la maladie artérielle périphérique, la néphropathie, la durée plus longue de la DS et le peptide natriurétique de type N-terminal pro-B supérieur (NT-proBNP). Le traitement de chaque pathologie en présence de l'autre pose des difficultés dans la pratique clinique. Le traitement de première intention de la DS chez les patients atteints d'IC devrait inclure la metformine et les inhibiteurs de SGLT2; à l'inverse, la saxagliptine, la pioglitazone et la rosiglitazone ne sont pas recommandées chez les patients atteints de DS et d'HF.

show abstract

Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension

Abstract: New generation beta-blockers, carvedilol and nebivolol, efficiently and similarly decrease blood pressure. They have similar favorable effects on glucose, insulin, IR, and the lipid profile.

Cited by 21 publications

References 15 publications

<p>Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia</p>

<p>Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia</p>

Nebivolol in the treatment of arterial hypertension

Chronic heart failure and diabetes mellitus: two unsuitably matched partners

Contact Info

Product

Resources

About